THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific’s latest quarter shows higher EPS and revenue, strong liquidity, and a near‑52‑week high—making it a top‑tier life‑science investment.

Thermo Fisher Scientific delivers steady, “in‑line” earnings but lacks a breakthrough growth engine—solid for stability, but limited upside for high‑risk investors.

Thermo Fisher Scientific rises 1.18% to $698.13, driven by strong earnings, organic growth and a shift toward high‑quality medical providers – see why investors stay optimistic.

Thermo Fisher Scientific stock dips 1.54% to $684.14 as investors eye its upcoming earnings and healthcare stability, maintaining an overweight rating.